The effect of the first-generation
HCV-protease inhibitors boceprevir and
telaprevir and the relation to baseline
NS3 resistance mutations in genotype 1:
experience from a small Swedish cohort.
Kjellin M, Wesslén T, Löfblad E,et
al
Ups J Med Sci.
2018 Mar 14:1-7
Abstract
Boceprevir and
Antiretroviral Pharmacokinetic
Interactions in HIV/HCV Co-infected
Persons: AIDS Clinical Trials Group
Study A5309s.
Kiser JJ, Lu D, Rosenkranz SL, Morse GD,
et al
Drugs R D.
2017 Sep
Abstract
Boceprevir-based triple
therapy to rescue HCV genotype 1/HBV
dually infected patients refractory to
peginterferon plus ribavirin combination
therapy in Taiwan.
Hsieh MH,
Yeh ML, Su TH,
et al
J Formos
Med Assoc.
2017 Jul 7
Abstract
Exploring resistance
pathways for first-generation NS3/4A
protease inhibitors boceprevir and
telaprevir using Bayesian network
learning.
Cuypers L, Libin P, Schrooten Y, et al
Infect
Genet Evol.
2017 May 9.
Abstract
Efficacy and safety
profile of boceprevir- or
telaprevir-based triple therapy or dual
peginterferon alfa-2a or alfa-2b plus
ribavirin therapy in chronic hepatitis
C: the real-world PegBase observational
study.
Mangia
A, Foster GR, Berg CP, et al
Ann Gastroenterol.
2017;30(3):327-343.
Abstract
Aplastic Anemia and Severe
Myelosuppression with Boceprevir or
Simeprevir-Containing Hepatitis C Virus
Treatment.
Senín A, Broquetas T, Cañete N,
et a|
,l Ann Hepatol.
2017 Feb 15;16(2):312-317.
Abstract
Rapid virological response of telaprevir
and boceprevir in a Brazilian cohort of
HCV genotype 1 patients: a multicenter
longitudinal study.
Borba
HH, Wiens A, Steimbach LM,
Ther Clin Risk Manag.
2017 Jan 10;
Abstract
Boceprevir or telaprevir
in hepatitis C virus chronic infection:
The Italian real life experience.
Cleo Study Group, Ascione A, et al
i LE,World
J Hepatol. 2016 Aug 8;
Abstract
Efficacy and safety of boceprevir-based
triple therapy in HCV cirrhotic patients
awaiting liver transplantation (ANRS
HC29 BOCEPRETRANSPLANT).
Fontaine H, Maynard M, Bouix
C,. et al
Clin Res Hepatol Gastroenterol.
2016 Aug 20.
Abstract
Optimisation of triple therapy for
patients with chronic hepatitis C: a
systematic review.
Pecoraro V, Cariani E, Villa
E, Trenti T.
Eur
J Clin Invest.
2016 Aug;46(8):737-48.
Abstract
Addition of boceprevir to
PEG-interferon/ribavirin in
HIV-HCV-Genotype-1-coinfected,
treatment-experienced patients:
efficacy, safety, and pharmacokinetics
data from the ANRS HC27 study.
Poizot-Martin I, Bellissant E,
et al
HIV Clin Trials.
2016 Mar;17(2):63-71
Abstract
FULL-TEXT ARTICLE
Boceprevir plus peginterferon/ribavirin
for treatment of chronic hepatitis C in
Russia
Isakov V, Nikitin I, Chulanov V,
Ogurtsov P, et al
World J Hepatol.
2016 Feb 28;8(6):331-
Paper
FULL-TEXT ARTICLE
Impact of IL28B, APOH and ITPA
Polymorphisms on Efficacy and Safety of
TVR- or BOC-Based Triple Therapy in
Treatment-Experienced HCV-1 Patients
with Compensated Cirrhosis from the ANRS
CO20-CUPIC Study
About F, Oudot-Mellakh T, Niay J,
et al
PLoS One.
2015 Dec 15;10(12):e0145105.
Paper
FULL-TEXT ARTICLE
Boceprevir for chronic HCV genotype 1
infection in treatment-experienced
patients with severe fibrosis or
cirrhosis: The Greek real-life
experience.
Manolakopoulos S, Kranidioti H, Goulis
J,
et al
Ann Gastroenterol.
2015 Oct-Dec;28(4):481-6.
Paper
FULL-TEXT ARTICLE
Boceprevir-Based Triple Antiviral
Therapy for Chronic Hepatitis C Virus
Infection in Kidney-Transplant
Candidates
Mehawej M, Rostaing L, Alric L, et al
J Transplant.
2015;2015:159795
Paper
IL28B genotype predicts
response to chronic hepatitis C triple
therapy with telaprevir or boceprevir in
treatment naïve and
treatment-experienced patients other
than prior partial- and null-responders.
Calisti G, Tavares A, Macartney MJ,
et al
Springerplus.
2015 Jul 16;4:357.
Abstract
Molecular principles
behind Boceprevir resistance due to
mutations in hepatitis C NS3/4A
protease.
Nagpal N,
Goyal S, Wahi D, et al
Gene.
2015 Jun 5. pii:
S0378-1119(15)00716-
Abstract
Lead-in period and week 8
as predictive tools for response to
boceprevir therapy: a retrospective
study of Spanish real clinical practice
Crespo J, Berenguer
M, Pérez F, Fernández I, et al
Gastroenterol Hepatol.
2015 May 11
Abstract
Treatment Patterns,
Health Care Resource Utilization, and
Costs in U.S. Patients Diagnosed with
Chronic Hepatitis C Infection Who
Received Telaprevir or Boceprevir.
Le TK, Kalsekar A, Macaulay D, et al
J Manag Care Spec Pharm.
2015 Apr;21(4):308-318.
Abstract
Intracellular
accumulation of boceprevir according to
plasma concentrations and
pharmacogenetics.
Cusato J, Allegra S,
De Nicolò A, et al
Int J Antimicrob Agents.
2015 Mar 14
Abstract
FULL-TEXT ARTICLE
First-generation protease
inhibitor-triple therapy: SVR 24,
safety, and predictors of response in a
large single center cohort.
Werner CR, Franz C, Egetemeyr DP,
et al
Virol J.
2015 Mar 3;12(1):37.
Paper
Telaprevir- and
Boceprevir-Based Triple Therapy for
Hepatitis C in Liver Transplant
Recipients With Advanced Recurrent
Disease: A Multicenter Study.
Verna EC, Saxena V, Burton JR Jr,
et al
Transplantation.
2015 Feb 24.
Abstract
A Phase I study to assess
the safety, tolerability and
pharmacokinetic profile of boceprevir
and sildenafil when dosed separately and
together, in healthy male volunteers.
Mora-Peris
B, Else L, Goldmeier D, et al
J Antimicrob Chemother.
2015 Feb 17.
Abstract
Pharmacokinetic
interaction between HCV protease
inhibitor boceprevir and methadone or
buprenorphine in subjects on stable
maintenance therapy.
Hulskotte EG,
Bruce RD, Feng HP, et al
Eur J Clin Pharmacol.
2015 Feb 11.
Abstract
Virological outcomes and
treatment algorithms utilisation in
observational study of patients with
chronic hepatitis C treated with
boceprevir or telaprevir.
Sterling RK, Kuo A,
Rustgi VK, et al
Aliment Pharmacol Ther.
2015 Jan 28
Abstract
Early virological
assessment during telaprevir- or
boceprevir-based triple therapy in
hepatitis C cirrhotic patients who
failed a previous interferon based
regimen - The ANRS CO20-CUPIC study.
Bailly F, Virlogeux V,
Dufour C, et al
Clin Res Hepatol
Gastroenterol.
2015 Jan 27. pii: S2210-7401(15)00002-9
Abstract
Long-term follow-up of patients
receiving boceprevir for
treatment of chronic hepatitis C.
Howe AY, Long J, Nickle D,
et al
Antiviral Res.
2015 Jan;113:71-8
Abstract
Boceprevir and telaprevir for chronic genotype 1 hepatitis C
virus infection. A systematic review and meta-analysis.
Manzano-Robleda
MD, Ornelas-Arroyo V, et al
Ann
Hepatol. 2015 Jan-Feb 2015;14(1):46-57.Z
Abstract
Virologic response and haematologic
toxicity of boceprevir- and
telaprevir-containing regimens in actual
clinical settings.
Butt AA, Yan P, Shaikh
OS, et al
J Viral Hepat.
2014 Dec 18.
Abstract
FULL-TEXT ARTICLE
Boceprevir is highly effective in
treatment-experienced hepatitis C
virus-positive genotype-1 menopausal
women.
Bernabucci V, Ciancio A,
Petta S, et al
World J Gastroenterol.
2014 Nov 28;20(44):16726-33.
Paper
Drug-drug interactions of
telaprevir and boceprevir in
HCV-monoinfected and HIV/HCV-coinfected
patients can modify the adherence.
Gonzalez-Colominas
E, Broquetas T, et al
Liver Int.
2014 Nov 10.
Abstract
Undetectable HCV-RNA at
treatment-week 8 results in
high-sustained virological response in
HCV G1 treatment-experienced patients
with advanced liver disease: the
International Italian/Spanish
Boceprevir/Peginterferon/Ribavirin Name
Patients Program.
Bruno S,
Bollani S, Zignego AL, et al
J Viral Hepat.
2014 Oct 14.
Abstract
Drug-drug Interaction
with Telaprevir or Boceprevir in Liver
Transplant Patients: About Four Cases
Delaborde L,
Logerot S, Fonrose X.
Therapie.
2014 Oct 17
Abstract
Safety Profile of Boceprevir and
Telaprevir in Chronic Hepatitis C:
Real-World Experience From HCV-TARGET.
Gordon SC, Muir AJ, Lim JK, et al
J Hepatol.
2014 Sep 9. pii: S0168-8278(14)00647-3
Abstract
Treatment of chronic
hepatitis with boceprevir leads to
remission of porphyria cutanea tarda.
Aguilera P,
Laguno M, To-Figueras J.
Br J Dermatol.
2014 Aug 25.
Abstract
Lack of Clinically
Significant Pharmacokinetic Interaction
Between the Thrombopoietin Receptor
Agonist Eltrombopag and Hepatitis C
Virus Protease Inhibitors Boceprevir and
Telaprevir.
Wire MB,
Fang L, Hussaini A, et al.
Antimicrob Agents Chemother.
2014 Aug 25.
Abstract
FULL-TEXT ARTICLE
Prediction of treatment week eight
response & sustained virologic response
in patients treated with boceprevir plus
peginterferon alfa and ribavirin.
Thompson A, Devine S, Kattan M, Muir A.
PLoS One.
2014 Aug 1;9(8):e103370
Paper
Hepatitis C virus NS3
protease genotyping and drug
concentration determination during
triple therapy with telaprevir or
boceprevir for chronic infection with
genotype 1 viruses, southeastern France.
Aherfi S, Solas C, Motte A, et al
J Med Virol.
2014 Jul 23.
Abstract
Effects of boceprevir and
telaprevir on the pharmacokinetics of
dolutegravir.
Johnson M,
Borland J, Chen S,
et al
Br J Clin Pharmacol.
2014 May 16
Abstract
Acute pancreatitis associated with
boceprevir: a case report.
Bilar JM, de Carvalho-Filho RJ, Mota CF,
et al
Braz J Infect Dis.
2014 May 12.
Abstract
Safety & Efficacy of
Boceprevir/Peginterferon/Ribavirin for
HCV G1 Compensated Cirrhotics:
Meta-Analysis of 5 Trials.
Vierling JM, Zeuzem S, Poordad F, et al
J Hepatol.
2014 Apr 17.
Abstract
The
cost-effectiveness of boceprevir for
hepatitis C.
Neoh CF, Kong DC.
Expert Rev Pharmacoecon Outcomes Res.
2014 Apr 8
Abstract
Effectiveness of
Telaprevir or Boceprevir in
Treatment-experienced Patients with HCV
Genotype 1 Infection and Cirrhosis.
Hezode
C, Fontaine H, Dorival C, et al
Gastroenterology.
2014 Apr 3.
Abstract
Telaprevir or boceprevir triple therapy
in patients with chronic hepatitis C and
varying severity of cirrhosis.
Saxena V,
Manos MM, Yee HS, et al
Aliment
Pharmacol Ther.
2014 Mar 24
Abstract
Telaprevir or Boceprevir
Based Therapy for Chronic Hepatitis C
Infection: Development of Resistance
Associated Variants in Treatment
Failure.
Macartney MJ,
Irish D, Bridge SH, Garcia-Diaz A,
et al
Antiviral Res.
2014 Mar 1.
Abstract
How to optimize current therapy of HCV
genotype 1 infection with boceprevir.
Bourlière M, Adhoute X, Wendt A,
et al
Liver Int.
2014 Feb;34 Suppl 1:4-10
Abstract
Liver transplantation in a child with
multifocal hepatocellular carcinoma
hepatitis C and management of
post-transplant viral recurrence using
boceprevir.
Malik S, Dekio F, Wen JW.
Pediatr Transplant.
2014 Jan 11
Abstract
Boceprevir for Chronic HCV Genotype 1
Infection in Patients with Prior
Treatment Failure to
Peginterferon/Ribavirin, including Prior
Null Response.
Vierling
JM, Davis M, Flamm S, et al
J Hepatol. 2013 Dec 19.
Abstract
Similar Effectiveness of Boceprevir and
Telaprevir Treatment Regimens for
Hepatitis C Virus Infection, Based on a
Nationwide Study of Veterans.
Ioannou
GN, Beste LA, Green PK.
Clin Gastroenterol Hepatol.
2013 Dec 17
Abstract
The Effects of Boceprevir and Telaprevir on the Pharmacokinetics of
Maraviroc: An Open Label, Fixed -Sequence Study in Healthy Volunteers.
Vourvahis M, Plotka A, Kantaridis C, et al
J Acquir Immune Defic Syndr.
2013 Dec 16.
Abstract
First case
of Drug Rash Eosinophilia and Systemic
Symptoms due to Boceprevir.
Samain A,
Duval-Modeste AB, Joly P, et al
J Hepatol.
2013 Dec 12
Abstract
Hepatitis C virus NS3
inhibitors: current and future
perspectives.
Salam KA, Akimitsu N.
Biomed Res Int.
2013;2013:467869..
Abstract
A Modified Ribavirin-free Interferon Therapy With Boceprevir in Post-Liver
Transplant Recurrent Hepatitis C.
Maticic
M, Luznik Z, Stepec S, Popovic P,
J
Clin Gastroenterol. 2013 Nov
21.
Abstract
Efficacy and safety of telaprevir and boceprevir in
patients with hepatitis C genotype 1: a meta-analysis.
Park C, Jiang S, Lawson KA.
J Clin Pharm Ther.
2013 Nov 16
Abstract
Seizures in Patients with Chronic Hepatitis C Treated with NS3/4A Protease
Inhibitors: Does Pharmacological Interaction Play a Role?
Milazzo L, Falvella FS, Magni C, et al
Pharmacology. 2013 Oct
31;92(5-6):235-237z
Abstract
Boceprevir Plus Peginterferon α-2b/Ribavirin in Chronic Hepatitis
C Genotype 1: Impact of Baseline Viral Load on Sustained Virologic Response.
Gordon SC, Reddy KR,
Jacobson IM, et al
J Clin Gastroenterol.
2013 Oct 30
Abstract
The pharmacokinetic evaluation of boceprevir for treatment of
Hepatitis C virus.
Shankar H, Bichoupan K, Dieterich DT.
Expert Opin Drug Metab Toxicol.
2013 Oct 1
Abstract
Documents
identified with this icon are in Portable Document Format (PDF) and require the
Telaprevir